Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

Vanguard Health Care ETF (VHT) is the affordability leader with a 0.09% expense ratio versus VanEck Pharmaceutical ETF (PPH) at 0.36%, while PPH’s 1-yr total return is higher (28.7% vs 25.7%). Over 5 years, VHT reduced drawdown risk (max drawdown -17.7% vs -20.3%) but PPH delivered stronger cumulative growth (growth of $1,666 vs $1,323 from $1,000). PPH also has a higher trailing dividend yield (2.0% vs 1.6%) but comes with elevated concentration risk (26 holdings; top holdings ~50% of value).

Analysis

This is more a vehicle-selection issue than a sector signal. The market is effectively being asked whether it wants broad healthcare carry or a concentrated pharma bet masquerading as diversification; that matters because the concentrated product is far more exposed to single-name idiosyncrasy, especially its largest weight. In practice, the higher recent return is mostly a function of a few megacap drug winners, so incremental upside from here is less about “healthcare” and more about whether the dominant growth names keep compounding at the same pace.

The bigger second-order effect is that the broader fund can outperform if healthcare leadership rotates away from the GLP-1 and patent-expiry complex into hospitals, medtech, managed care, and tools. That rotation is plausible over 1-3 months if investors start pricing a softer macro landing and rate-sensitive defensive allocation, because those subsectors benefit from steadier utilization and lower multiple risk than pharma-only exposure. Conversely, if pricing pressure or drug-policy headlines reappear, the concentrated fund will underperform the broad basket by more than the headline sector move because of its top-heavy structure.

Consensus is probably overrating the trailing return gap and underrating drawdown asymmetry. The right question is not which ETF “won” recently, but which structure gives cleaner exposure per unit of risk: the lower-fee broad basket is the cleaner core holding, while the concentrated fund is only attractive if you explicitly want amplified exposure to the largest pharma names. Falsifier for a relative-value view: continued outperformance from the dominant pharma weights without any gap in earnings revisions, in which case concentration was rewarded and the basket premium was justified.

Key Decisions for Investors

• Prefer VHT over PPH as the core healthcare allocation over the next 3-12 months; the fee gap and diversification make it the better risk-adjusted holder if the goal is sector beta rather than a pharma-specific view.
• Relative-value trade: long VHT / short PPH in a small size for 1-3 months to isolate concentration risk. Thesis breaks if LLY-driven pharma momentum persists and PPH outperforms VHT by >5% without broader healthcare participation.
• If you want pure drug exposure, own the underlying names directly instead of paying an ETF wrapper premium: focus on LLY, MRK, NVS, or ABBV depending on whether you want growth, defensive cash flow, or dividend support.
• Set an alert around the next LLY earnings/guidance cycle; that is the most likely catalyst to move PPH materially, and a single miss or cautious revision would likely hit PPH harder than VHT.